<P>&nbsp;</P> <P align=justify><STRONG><STRONG><A title="" href="https://www.aderly.com/lyon-economic-news/sciences-du-vivant-news-ERYTECH-PHARMA-INITIATES-A-CLINICAL-STUDY-IN-ACUTE-LYMPHOBLASTIC-LEUKEMIA-,n,7167,EN.jsp" target=_blank>Erytech Pharma is a French biopharmaceutical company </A></STRONG>created in 2004, whose production facilities are based in Lyon</STRONG>, counting nearly 40 employees.</P> <P align=justify>&nbsp;</P> <P align=justify>In a few years, it has become a <STRONG><STRONG><A title="" href="https://www.aderly.com/pharmaceutique_biotech/index,p,100044,EN.jsp" target=_blank>late-stage biopharmaceutical company </A></STRONG>thanks to its methodical development regarding innovative treatments for acute leukemia</STRONG>. It has developed Graspa<SUP>&#174;</SUP>, an innovative concept based on destroying cancerous cells by eliminating their essential nutritive elements.</P> <P align=justify>&nbsp;</P> <P align=justify>On 23<SUP>rd</SUP> April 2013, Erytech Pharma has announced <STRONG>the success of its IPO (initial public offering) in the NYSE Euronext regulated market in Paris, raising &#8364;16.7 million</STRONG>, a million more than the expected target amount of &#8364;15 million. The price for the Global Placement and the Open Price Offering was set at the middle of the indicative range, at &#8364;11.60.</P> <P align=justify>&nbsp;</P> <P align=justify><STRONG>Gil Beyen, Chairman of Erytech Pharma, thanks every shareholder</STRONG> for &#8220;<EM>their confidence and for their decision to support the development of a unique biopharmaceutical company in France, both in terms of the innovative nature of its technology and its high degree of progress</EM>&#8221;. <BR></P>